Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Gains from Sales and Divestitures: 2022-2025

  • Cellebrite DI's Gains from Sales and Divestitures rose 273.74% to $6.4 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $6.4 billion, marking a year-over-year increase of 273.74%. This contributed to the annual value of $7.3 billion for FY2024, which is N/A change from last year.
  • As of Q2 2025, Cellebrite DI's Gains from Sales and Divestitures stood at $6.4 billion, which was down 12.43% from $7.3 billion recorded in Q4 2024.
  • Over the past 5 years, Cellebrite DI's Gains from Sales and Divestitures peaked at $7.3 billion during Q4 2024, and registered a low of -$134,243 during Q2 2022.
  • Its 3-year average for Gains from Sales and Divestitures is $3.8 billion, with a median of $4.0 billion in 2024.
  • Data for Cellebrite DI's Gains from Sales and Divestitures shows a peak YoY spiked of 139,959.07% (in 2024) over the last 5 years.
  • Over the past 4 years, Cellebrite DI's Gains from Sales and Divestitures (Quarterly) stood at -$134,243 in 2022, then skyrocketed by 1,008.44% to $1.2 million in 2023, then soared by 139,959.07% to $7.3 billion in 2024, then soared by 273.74% to $6.4 billion in 2025.
  • Its last three reported values are $6.4 billion in Q2 2025, $7.3 billion for Q4 2024, and $1.7 billion during Q2 2024.